April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.

The Plan was adopted by the Company’s Board of Directors on August 5, 2022. Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for ...

Climb Bio, Inc., a pharmaceutical company specializing in preparations with a market capitalization of $82.32 million, announced the expansion of its board of directors and the departure of two ...

MINNEAPOLIS - Bio-Techne (NASDAQ:TECH) Corporation (NASDAQ: TECH), a global life sciences company valued at $11.45 billion, has announced the appointment of Dr. Amy E. Herr as an independent ...